Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Below, AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 81 - 90 out of 181

AMIA Supports VA Telehealth Expansion Proposal

November 2, 2017

AMIA provided comments to a VA proposed rule that would allow its providers to furnish telehealth services, regardless of the state or location where they or the beneficiary is physically located. AMIA supported the proposal, while emphasizing that any telehealth applications use nationally recognized health IT standards and enable use […]

AMIA Comments on CY Physician Fee Schedule NPRM

September 11, 2017

Today, AMIA responded to a CMS Proposed Rule on the CY 2018 Physician Fee Schedule. AMIA supported many of the proposals, including a proposal to begin the Appropriate Use Criteria Program in 2019 and proposed changes to E/M documentation guidelines.

AMIA Supports ONC Efforts to Develop Trusted Exchange Framework

August 24, 2017

In comments submitted August 24, AMIA submitted comments to ONC regarding the development of a Trusted Exchange Framework and Common Agreement as required by the 21st Century Cures Act. AMIA recommended ONC look to use the Framework to provide a floor upon which existing networks – and new networks – […]

AMIA Supports Year 2 Quality Payment Program Proposals

August 21, 2017

Today, AMIA responded to a CMS Proposed Rule on Year 2 of the Quality Payment Program. AMIA supported many of the new flexibilities offer to eligible clinicians to participate in MIPS or advanced alternative payment models. The organization also urged CMS to require 2015 Edition CEHRT beginning in 2019.

AMIA Supports ONC Draft Framework to Measure Use of Interoperability Standards

July 25, 2017

AMIA submitted comments supporting ONC’s draft framework, recommending a measurement approach that focuses on the clinician and patient experience. AMIA also underscored the need to have the benefits of measurement outweigh the costs, and urged federal officials to provide sufficient support to develop and implement automated measurement solutions.

AMIA Supports Federal Health IT Research & Development Framework

July 12, 2017

In comments submitted to the Networking and Information Technology Research and Development (NITRD) Program, the nation’s leading biomedical and health informaticians applauded federal officials for developing a draft strategic framework for health IT research and development (R&D). AMIA provided a series of recommendations highlighting the need for R&D related to […]

AMIA Applauds Flexibilities, Supports 2015 CEHRT Timeline in IPPS Proposed Rule

June 13, 2017

In comments to CMS, AMIA supported proposals to reduce the number of required quality measures and new proposed reporting period flexibilities, while also recommending additional such flexibilities for the 2018 Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs. AMIA additionally agreed with the proposed rule’s analysis that […]

AMIA Responds to FCC Notice on Broadband-Enabled Health Technology

May 24, 2017

In comments submitted to the Federal Communications Commission, AMIA recommended FCC view broadband access as a social determinant of health and pursue policies that enable patients to participate in the fast-changing mobile health ecosystem.  AMIA also recommended several potential areas of collaboration and provided a set of relevant scholarship to […]

AMIA Response to NLM Strategic Plan

January 31, 2017

In comments submitted to the National Library of Medicine, AMIA said members envision a future where NLM leads the medical and research enterprise in demonstrating how real-world and “big” health data can be leveraged to develop new concepts of human disease, design novel therapies, and train future clinicians and researchers.